ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0812

A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares

Abhimanyu Amarnani1, Cristobal Rivera-Martinez1, Marc Scherlinger2, Doua Azzouz1, Andy Lee1, Kate Trujillo1, MacIntosh Cornwell1, Tyler Weinstein1, Tatiana Borja3, Bharati Matta4, Sharon Chung5, Laura Cooney6, Uzair Chaudhary1, Steven Medvedovsky1, Peter Izmirly1, Jill Buyon1, Patrick Blanco7, Betsy Barnes8, Bhama Ramkhelawon1, Kelly Ruggles9 and Gregg Silverman1, 1New York University Grossman School of Medicine, New York, NY, 2Strasbourg University Hospital, Strasbourg, France, 3Feinstein Institutes for Medical Research, New York, NY, 4The Feinstein Institutes for Medical Research, Manhasset, NY, 5University of California, San Francisco and Immune Tolerance Network, San Francsico, 6University of Michigan and Immune Tolerance Network, Ann Arbor, MI, 7UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, 8Feinstein Institutes for Medical Science, Manhasset, NY, 9NYU Grossman School of Medicine, Brooklyn, NY

Meeting: ACR Convergence 2024

Keywords: Lupus nephritis, microbiome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: SLE is a leading cause of premature death, often from severe complications including lupus nephritis (LN), especially in disadvantaged groups. Despite advances in treatment, 10-30% of patients with LN progress to end-stage kidney disease. While disease-associated dysbiosis within gut microbiota has been reported, causative roles remain poorly understood. We found ~40% of LN flares are associated with gut blooms of Ruminococcus gnavus (RG) strains expressing a novel cell wall lipoglycan (LG)1,2,3. We sought to define underlying in vivo pathogenic pathways.

Methods: Patients in three LN cohorts, NYU, and the validation cohorts: Bordeaux Hospital University and ITN_ACCESS_LN, were investigated with a quantitative bead-based assay for serum anti-LG IgG (Fig1A). Bulk whole-blood RNA-seq libraries were analyzed for gene and GSEA pathway representation. PF4/CXCL4 levels were assessed by ELISA and platelet-derived microparticles (MPs) by microfluorimetry. NETosis was measured via immunoassays for serum citrullinated histone-H3, DNA, and myeloperoxidase. To assess causation, naïve C57BL/6 female mice were gut-colonized with an LG-producing RG strain, and then whole-blood RNA-seq and flow cytometry were performed.

Results: In LN validation cohort patients with high anti-LG levels, whole-blood RNAseq revealed increased signatures for platelet activation and degranulation (qval< 4.4E-4), neutrophil degranulation (qval< 0.007), and myeloid leukocyte activation (qval< 0.002), independent of type I IFN signatures (Fig1B). Higher levels of PF4, a platelet granule protein, were associated with high anti-LG levels (p< 0.04)(Fig1C) and significantly higher NETosis fragments were also detectable in anti-LG positive LN patients (p< 0.02, Fig1D). Active-LN patients from the Bordeaux Hospital University cohort showed a positive trend between anti-LG levels and P-selectin+ platelet MPs. In these studies, anti-dsDNA levels did not correlate with platelet activation or NETosis. In mice colonized with LG-producing RG (Fig2A), blood-bulk RNAseq showed an increased platelet degranulation gene signature (p< 0.002, Fig2B). Notably, SPARC, PDGFA, and VTI1B were significantly increased in RG-colonized mice (p< 0.05), just as in LN patients. RG-colonization induced ex vivo platelet sensitization after thrombin challenge, detected as raised surface P-selectin levels (p<0.016)(Fig2C).

Conclusion: Our findings provide the first evidence that RG intestinal blooms trigger LN flares linked to platelet activation with MP formation and downstream NETosis (Fig3), in a type-I IFN-independent setting. Using the anti-LG antibody as a companion diagnostic, this set of active LN patients should be evaluated for therapeutic interventions of platelet activation and NETosis.

References:        
1. Azzouz, D et al. ARD 2019

2. Azzouz, D et al. ARD 2023

3. Silverman, GJ et al. NRR 2023

Supporting image 1

LN with high antibody responses to RG cell wall lipoglycan (LG) have increased platelet activation. (A) Ruminococcus gnavus (RG) serum anti-LG levels in Healthy-Ctrls, non-renal SLE, and SLE patients with documented intestinal blooms of RG by 16S rRNA sequencing (SLE RG bloom) or without blooms (Renal No-Bloom) from our NYU cohort, compared to patients with negative (<5.3x10^4) or positive anti-LG levels (as a horizontal dashed line) from the validation ACCESS_LN and Bordeaux cohorts. (B) Unsupervised hierarchical clustering heatmap of gene expression in platelet activation and degranulation, neutrophil degranulation, and myeloid leukocyte activation pathways in patients with negative vs positive anti-LG antibody levels from ACCESS_LN. Pathway analysis represents ordered query functional profiling gene set enrichment analysis gene ontology results. No significant pathway enrichment was observed for type I interferon related genes. (C) PF4/CXCL4 levels in sera dichotomized for anti-LG level in ACCESS_LN samples. (D) ELISA of serum NET fragments from active LN dichotomized by anti-LG antibody levels. P-values represent non-parametric, Mann-Whitney U tests.

Supporting image 2

Murine RG gavage drives platelet activity in whole blood RNAseq and flow cytometry studies of ex-vivo platelets 2 weeks post gavage. (A) Protocol for antibiotic pretreatment, gavage of RG or sham, and sample collection. (B) Volcano plot of gene expression 2 weeks post gavage with genes related to platelet degranulation noted. (C) Flow cytometry of murine ex-vivo platelet activation from whole-blood 2-weeks post RG gavage with stimulation of PBS or thrombin in C57BL/6 (top) and C57BL/6-Gp1b tdTomato mice. P-values represent non-parametric, Mann-Whitney U test. No significant differences for ADP or collagen stimulation were observed.

Supporting image 3

A model of SLE pathogenesis in which RG intestinal blooms increases gut permeability and translocation of microbial products, resulting in systemic immune exposure to RG surface lipoglycan (LG) and downstream platelet activation, microparticle release, and NETosis responsible for glomerular injury. Adapted from Silverman et al. Nature Reviews Rheumatology 2023, and Scherlinger et al. Nature Reviews Immunology 2023.


Disclosures: A. Amarnani: None; C. Rivera-Martinez: None; M. Scherlinger: None; D. Azzouz: None; A. Lee: None; K. Trujillo: None; M. Cornwell: None; T. Weinstein: None; T. Borja: None; B. Matta: None; S. Chung: None; L. Cooney: None; U. Chaudhary: None; S. Medvedovsky: None; P. Izmirly: Hansoh Bio, 2; J. Buyon: Artiva Biotherapeutics, 1, Bristol-Myers Squibb(BMS), 1, 2, Equillium, 1, GlaxoSmithKlein(GSK), 1, 2, Otsuka Pharmaceuticals, 1, Related Sciences, 1, 2; P. Blanco: None; B. Barnes: None; B. Ramkhelawon: None; K. Ruggles: None; G. Silverman: None.

To cite this abstract in AMA style:

Amarnani A, Rivera-Martinez C, Scherlinger M, Azzouz D, Lee A, Trujillo K, Cornwell M, Weinstein T, Borja T, Matta B, Chung S, Cooney L, Chaudhary U, Medvedovsky S, Izmirly P, Buyon J, Blanco P, Barnes B, Ramkhelawon B, Ruggles K, Silverman G. A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-human-gut-pathobiont-drives-platelet-activation-with-microparticle-release-and-netosis-during-lupus-nephritis-flares/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-human-gut-pathobiont-drives-platelet-activation-with-microparticle-release-and-netosis-during-lupus-nephritis-flares/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology